Real-World data reveals palbociclib use in japanese breast cancer patients
NCT ID NCT05153187
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed medical records of 1,170 advanced breast cancer patients in Japan to see how they used the drug palbociclib (Ibrance). Researchers looked at blood test frequency and how long patients stayed on treatment. The goal was to describe real-world treatment patterns, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- palbociclib (Ibrance)
- What this could lead to
- If successful, this could help doctors better understand how palbociclib is used in real-world settings, potentially improving treatment guidelines for advanced breast cancer in Japan.
- What could go wrong
- This is an observational study that only describes existing data, not testing a new treatment. It cannot prove what works best, and results may not apply outside Japan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,170 people
The number who actually took part.
- Started
-
Aug 2019
- Finished
-
Jun 2021
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Japanese patients with diagnosis of breast cancer, diagnosis of secondary malignant neoplasm and who received endocrine therapy drugs and who didn't receive anti-HER2 therapy drugs (defined as HR+/HER2- breast cancer) and whose data were registered into the MDV database from April 2008
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of breast cancer based on International statistical classification of diseases and related health problems 10th revision (International Statistical Classification of Diseases and Related Health Problems \[ICD-10\]) (C50.xx) * Received at least one prescription of endocrine therapy drugs * Diagnosis of secondary malignant neoplasm based on ICD-10 (C77.x, C78.x, C79.x ) Exclusion Criteria: -Received a prescription of anti-HER2 therapy (Trastuzumab, Trastuzumab emtansine, Pertuzumab, and Lapatinib tosilate hydrate)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Japan
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Two-Drug HER2 attack vs one: which First-Line strategy helps advanced breast cancer patients live longer?